Table 4 Effect of daily home fortification with 3Â mg iron as NaFeEDTA and 12.5Â mg iron as encapsulated ferrous fumarate on categorical outcomes at 30Â days after start of intervention, per protocol analysis
Outcome/intervention group | Prevalence | (n/n) | Effect (95% CI) relative to placebo |
|---|---|---|---|
Anaemia | |||
 Placebo | 53.3% | (56/105) | Reference |
 Iron, 3 mg as NaFeEDTA | 43.7% | (45/103) | –9.6% (–22.7% to 3.9%) |
 Iron, 12.5 mg as ferrous fumarate | 51.4% | (55/107) | –1.9% (–15.1% to 11.3%) |
Iron deficiencya | |||
 Placebo | 44.6% | (25/56) | Reference |
 Iron, 3 mg as NaFeEDTA | 24.5% | (12/49) | –20.2% (–36.4% to –18.5%) |
 Iron, 12.5 mg as ferrous fumarate | 30.5% | (18/59) | –14.1% (–30.7% to 3.5%) |
Plasmodium infection, by dipstick testb | |||
 Placebo | 16.2% | (17/105) | Reference |
 Iron, 3 mg as NaFeEDTA | 18.4% | (19/103) | 2.3% (–8.1% to 12.6%) |
 Iron, 12.5 mg as ferrous fumarate | 22.6% | (24/106) | 6.4% (–4.3% to 17.0%) |
P. falciparum infection, by microscopy | |||
 Placebo | 18.5% | (19/103) | Reference |
 Iron, 3 mg as NaFeEDTA | 15.5% | (15/97) | –3.0% (–13.4% to 7.6%) |
 Iron, 12.5 mg as ferrous fumarate | 15.2% | (15/99) | –3.3% (–13.6% to 7.2%) |